Furthermore, 8 has been granted accelerated approval by FDA for the treatment of late-stage NSCLC patients with EGFRT790M mutation-positive who have progressed after other EGFR TKIs therapy20. This evidence concerns the gene EGFR and non-small cell lung carcinoma.